Versant Bets $50M on Lycia to Make Protein Degraders Against Extracellular Targets

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Cygnal Therapeutics Zeroes in on Unorthodox, Peripheral Nervous System Approach to Cancer
Accent CEO Shakti Narayan on Targeting RNA-Modifying Proteins for Cancer
Switzerland: What Went Right, and How to Better Prepare for the Second Wave
Versant Ventures Reloads with $700M for Early-Stage Biotech